HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cancer drug AB801 enters human safety testing
Disease control OngoingThis early-stage study is testing a new drug, AB801, alone or with other treatments, in about 91 people with advanced cancers (like lung, colon, or breast cancer) that have not responded to standard therapies. The main goal is to check the drug's safety and find the best dose for…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Jul 02, 2026 01:00 UTC
-
New pill targets Hard-to-Treat cancers in early trial
Disease control OngoingThis study tests a new oral drug called IPN01194 in 36 adults with advanced solid tumours (melanoma, colorectal, pancreatic, or head and neck cancer) that have not responded to standard treatments. The goal is to find the right dose and check if it is safe, while also looking for…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Ipsen • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New cocktail of cancer drugs shows promise in early trial
Disease control OngoingThis study tests whether combining three different antibodies—BI 770371, pembrolizumab, and cetuximab—can shrink tumors in people with head and neck cancer that has spread or come back. About 91 adults are randomly assigned to one of three treatment groups. The goal is to see if …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could an immunotherapy combo replace harsh chemo for head and neck cancer?
Disease control OngoingThis phase II trial tests whether combining the immunotherapy drug durvalumab (Imfinzi) with radiation therapy can effectively treat intermediate-risk head and neck cancer after surgery, while causing fewer serious side effects than the standard cisplatin-based chemo-radiation. T…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug combo tested for tough cancers
Disease control OngoingThis early-stage trial tests a new drug called remzistotug, alone or with other cancer drugs, in 152 people with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. It is not yet known if the drug will sh…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Experimental combo targets Chemo-Resistant cancers
Disease control OngoingThis study tests an experimental drug called NEO-201 combined with the immunotherapy pembrolizumab in adults with advanced solid tumors that no longer respond to chemotherapy. The trial focuses on lung, head and neck, cervical, and uterine cancers. Researchers aim to find a safe …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Precision Biologics, Inc • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Cancer combo trial pulled before it even started
Disease control TerminatedThis study was designed for people with advanced head and neck cancer that had spread or come back. It aimed to test a combination of two drugs: decitabine (a chemotherapy drug) and nivolumab (an immunotherapy drug). The goal was to see if the combination was safe and could help …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug combo shows promise for tough head and neck cancers
Disease control OngoingThis early-phase trial tests a new drug called NT219 combined with either pembrolizumab or cetuximab in 29 adults with head and neck cancer that has returned or spread. The goal is to see if the combination shrinks tumors. Participants receive weekly NT219 plus one of the other d…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Immunotherapy boost before surgery shows promise against head and neck cancer
Disease control OngoingThis study tests whether adding an immunotherapy drug (treprizumab) to standard chemotherapy before surgery can improve outcomes for people with advanced head and neck cancer. About 122 participants will be randomly assigned to receive either the drug combo or chemo alone for thr…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests an experimental drug called INCB177054, given alone or with another drug (retifanlimab), in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Abo…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Head and neck cancer: which chemo combo works best?
Disease control OngoingThis study compares two chemotherapy combinations for people with advanced head and neck cancer that hasn't been treated yet. One group gets paclitaxel, carboplatin, and cetuximab weekly; the other gets cetuximab, docetaxel, cisplatin, and fluorouracil in cycles. The goal is to s…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
DNA vaccine combo takes on HPV head and neck cancer
Disease control OngoingThis phase 2 trial tests a combination of a DNA vaccine (GX-188E), an immune booster (GX-I7), and an immunotherapy drug (nivolumab) in 21 adults with HPV-related head and neck cancer that has returned or spread. The goal is to see if the combo can shrink tumors and improve surviv…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug AZD9592 enters first human trials for tough cancers
Disease control OngoingThis early-stage trial tests an experimental drug called AZD9592, alone or with other cancer drugs, in about 167 adults with advanced solid tumors (including lung, head & neck, and colorectal cancers). The main goals are to check safety, find the right dose, and see if the drug s…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug cocktail shows promise in battling advanced head and neck cancer
Disease control OngoingThis study tests whether adding two drugs, niraparib and dostarlimab, to standard radiation therapy can better control advanced head and neck cancer. About 34 adults with stage III or IV cancer will receive the drugs before, during, and after radiation. The goal is to see if this…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Grupo Español de Tratamiento de Tumores de Cabeza y Cuello • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Experimental triple therapy takes on head and neck cancer
Disease control OngoingThis early-phase trial tests a new drug called berzosertib (M6620) alongside standard chemotherapy (cisplatin) and radiation in people with advanced head and neck cancer that has spread to nearby tissues. The main goals are to find the safest dose and to see what side effects occ…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New Immune-Boosting drug GEN1042 tested in japanese cancer patients
Disease control OngoingThis early-stage study tests a new drug called GEN1042, which aims to help the immune system fight cancer. It is being tested alone or with other cancer drugs in 42 Japanese adults with advanced solid tumors. The main goal is to check safety and find the right dose.
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo targets Hard-to-Treat cancers with gene mutation
Disease control OngoingThis early-phase study tests a drug called inavolisib, alone or with atezolizumab, in people with cancers that have a specific change in the PIK3CA gene. The study includes patients with head and neck cancer that has returned or spread. The main goals are to check safety and see …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Experimental cocktail aims to tackle Hard-to-Treat head and neck cancer
Disease control OngoingThis early-phase trial is testing a new combination of an experimental drug (INCB081776), an immunotherapy (pembrolizumab), and radiation therapy in 10 people with advanced head and neck cancer that has spread or come back. The main goal is to check safety and side effects, while…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: EARLY_PHASE1 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
MRNA cancer shots: new hope or hype?
Disease control OngoingThis early-stage trial tests two experimental mRNA therapies (mRNA-4106 and mRNA-4200) in 42 people with advanced solid tumors like melanoma, lung, or liver cancer. Some participants receive the mRNA therapy alone, others get it combined with the immunotherapy drug pembrolizumab.…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New cancer drug shows promise in early trial
Disease control OngoingThis early-stage trial tests a new drug called LY4101174 in people with advanced solid tumors, including bladder, breast, and lung cancers. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The study will check if the drug is safe, tolerable, and ef…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New hope for hard-to-treat head and neck cancer: triple therapy trial underway
Disease control OngoingThis study tests a new three-drug combination for people with advanced head and neck cancer that came back or spread after platinum chemotherapy. The drugs aim to boost the immune system and attack cancer cells directly. About 64 adults will take part to see if the treatment is s…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Lyvgen Biopharma Holdings Limited • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Two-Drug punch before surgery shows promise against head and neck cancer
Disease control OngoingThis study tests whether giving two drugs (cetuximab and cemiplimab) before surgery can help shrink tumors in people with head and neck squamous cell carcinoma. About 22 adults will receive the combination before their planned surgery. The main goal is to see how many patients ha…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug combo shows promise for tough head and neck cancers
Disease control OngoingThis study tests whether adding the experimental drug ipatasertib to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with head and neck cancer that has returned or spread. About 52 adults with incurable, advanced squamous cell carcinoma w…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug combo aims to boost immune attack on head and neck tumors before surgery
Disease control OngoingThis study tests whether giving two drugs—nivolumab and an anti-IL-8 antibody—before surgery is safe and feasible for people with head and neck cancer. About 24 participants will receive the combination before their operation. The goal is to see if this approach can help shrink t…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug cocktail targets Hard-to-Treat tumors
Disease control OngoingThis early-stage trial tests a new oral drug called ceralasertib, given alone or with other cancer treatments like chemotherapy or targeted drugs, in 354 adults with advanced solid tumors that no longer respond to standard care. The main goal is to check safety and find the best …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New Antibody-Drug conjugate shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called SKB264 in people with advanced solid tumors that have not responded to standard therapies. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial includes over 1,400 participants with various …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Klus Pharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Immunotherapy combo may keep head and neck cancer at bay
Disease control OngoingThis phase 3 trial tests whether adding the immunotherapy drug pembrolizumab before and after surgery can help people with advanced head and neck cancer stay cancer-free longer. About 714 participants receive either pembrolizumab plus standard radiation (with or without chemo) or…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Could a diabetes drug boost cancer immunotherapy?
Disease control OngoingThis phase 2 trial tests whether adding metformin, a common diabetes drug, to the immunotherapy pembrolizumab (Keytruda) can help shrink tumors in people with metastatic head and neck cancer. The study enrolls 21 adults whose cancer has spread or returned and cannot be treated wi…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Trisha Wise-Draper • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Immune booster added to standard cancer care shows promise in early trial
Disease control OngoingThis phase 2 trial is testing whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard treatment—surgery, radiation, and sometimes chemotherapy—can help people with head and neck cancer live longer without the cancer returning. About 96 participants will receive…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Trisha Wise-Draper • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New cocktail aims to tame incurable head and neck cancer
Disease control OngoingThis study tests a three-drug combination called CACTUX (cisplatin, nab-paclitaxel, and cetuximab) in 74 people with head and neck cancer that cannot be cured. The goal is to see if this mix works better and causes fewer side effects than the standard treatment. Participants have…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental 'T cell Engager' takes on Hard-to-Treat cancers
Disease control OngoingThis early-phase trial is testing a new drug called IMA401, which helps the body's immune T cells attack cancer cells that have certain markers (MAGE-A4 or MAGE-A8). The study includes about 95 adults with advanced solid tumors that have come back or not responded to other treatm…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Immatics Biotechnologies GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Promising drug shrinks tumors in advanced cancers
Disease control OngoingThis study tested a drug called sacituzumab govitecan in 227 people whose solid tumors had spread to other parts of the body. The main goal was to see if the drug could shrink tumors. Researchers measured how many patients had their tumors shrink or disappear. This is not a cure,…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New drug combo shows promise in early cancer trial
Disease control OngoingThis early-phase trial tests a new drug called sEphB4-HSA combined with standard chemotherapy in people with advanced or metastatic solid tumors, including head and neck, pancreatic, lung, and gallbladder cancers. The goal is to find the best dose and see if the combination is sa…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New three-step combo targets tough head and neck cancers
Disease control OngoingThis study tests a three-step treatment plan for people with a type of head and neck cancer not caused by HPV. First, patients take a drug called palbociclib before standard chemoradiation, then receive chemoradiation, and finally take palbociclib again after treatment. The goal …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo therapy aims to shrink head and neck tumors before surgery
Disease control OngoingThis phase 2 trial tests giving the immunotherapy drug pembrolizumab (Keytruda) along with a short course of targeted radiation before surgery for people with advanced head and neck cancer. The goal is to see if this combination can shrink tumors more effectively and help preserv…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New combo immunotherapy drug enters human trials for 18 cancers
Disease control OngoingThis early-phase trial tests a new drug called AI-061, which combines two immune-boosting antibodies (anti-PD-1 and anti-CTLA-4) into one treatment. The study will enroll 18 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to find a safe…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Immune drugs given before surgery show promise against multiple cancers
Disease control OngoingThis phase 2 study is testing whether giving the immune-boosting drug cemiplimab (alone or with other drugs) before surgery can shrink tumors in people with non-small cell lung cancer, liver cancer, or head and neck cancer. About 65 participants will receive treatment before thei…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug combo aims to shrink Hard-to-Treat head and neck tumors
Disease control OngoingThis phase 2 trial tests two different doses of a nano-encapsulated chemotherapy drug called FID-007, combined with cetuximab, in 46 people with advanced head and neck cancer that has returned or spread. The goal is to see how well the combination shrinks tumors and to check for …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Fulgent Pharma LLC. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New cancer drug YL201 enters human testing for advanced tumors
Disease control OngoingThis study tests an experimental drug, YL201, in about 990 people with advanced solid tumors like lung, prostate, and liver cancers. The goal is to check safety and see if tumors shrink. It is an early-stage trial, so the drug is not yet proven to work.
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Could a few big doses of radiation before surgery beat head and neck cancer?
Disease control OngoingThis early-phase study is testing whether giving a shorter, more intense course of radiation before surgery is safe for people with head and neck cancer. The trial involves 12 adults with HPV-negative, surgically removable tumors. The main goal is to see if this condensed radiati…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug cocktail aims to shrink head and neck tumors better than standard care
Disease control OngoingThis study tests whether adding an experimental drug (domvanalimab) to a standard immunotherapy (zimberelimab) plus chemotherapy works better than the standard immunotherapy plus chemotherapy alone for people with head and neck cancer that has spread or come back. About 100 adult…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New biosimilar RPH-002 takes on erbitux in head and neck cancer showdown
Disease control OngoingThis phase 3 trial compares a new drug, RPH-002, to the standard treatment Erbitux in 161 patients with advanced head and neck cancer that cannot be removed by surgery. Both drugs are given with chemotherapy. The main goal is to see if RPH-002 works as well as Erbitux in shrinkin…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: R-Pharm • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Blue dye could boost radiation for tough head and neck cancers
Disease control OngoingThis early-phase study tests whether injecting methylene blue (a dye) directly into tumors can make radiation therapy work better for people with head and neck cancer that has come back and is resistant to radiation. Ten participants will receive weekly tumor injections plus dail…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: EARLY_PHASE1 • Sponsor: China Medical University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New dual-action antibody enters early trials for tough-to-treat cancers
Disease control OngoingThis early-phase study tests an experimental drug called MCLA-129, a bispecific antibody that targets two cancer-related proteins (EGFR and c-MET). It is for people with advanced non-small cell lung cancer, gastric cancer, esophageal cancer, head and neck cancer, or colorectal ca…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Merus B.V. • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Engineered immune cells take on advanced cancers in early trial
Disease control OngoingThis early-phase study tests whether a new treatment called KSQ-001EX is safe for people with advanced solid tumors like melanoma, lung cancer, or head and neck cancer. The treatment uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are genetically modified …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Donor immune cells take on Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase trial is testing a new type of cell therapy called P-MUC1C-ALLO1 for people with advanced solid tumors (like breast, ovarian, lung, or pancreatic cancer) that have not responded to other treatments. The therapy uses donor immune cells engineered to recognize and …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Poseida Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
HPV vaccine combo shows promise against head and neck cancer in early trial
Disease control OngoingThis study tests whether combining an HPV DNA vaccine with immunotherapy drugs can shrink advanced head and neck cancers caused by HPV types 16 or 18 before surgery. About 56 adults with resectable tumors will receive one of three treatment combinations. The main goal is to see i…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Smart scan could spare half the neck from radiation in head and neck cancer
Disease control OngoingThis study tests whether a special scan (SPECT/CT) can map where a head and neck tumor drains lymph fluid. If the scan shows no drainage to the opposite side of the neck, doctors can safely avoid radiating that side, reducing side effects. About 90 patients with newly diagnosed h…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New combo therapy hopes to shrink Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called HCB101 given together with other cancer treatments for people with advanced solid tumors that have not responded well to prior therapy. About 500 adults will take part to find the safest dose and see if the combination can shrink tumors. The goa…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: FBD Biologics Limited • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New Vaccine-Immunotherapy combo targets multiple cancers in early trial
Disease control OngoingThis phase 1 trial tests a vaccine (p53MVA) that trains the immune system to attack cancer cells with a p53 mutation, given together with the immunotherapy drug pembrolizumab (Keytruda). The study includes 11 people with advanced solid tumors like lung, head and neck, liver, kidn…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New combo therapy aims to reignite immune attack on drug-resistant tumors
Disease control OngoingThis study is for adults with advanced lung, skin, kidney, or head-and-neck cancers that have stopped responding to standard immunotherapy. The treatment combines an immune-boosting drug injected directly into a tumor, targeted radiation, and an immunotherapy drug (pembrolizumab)…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Megan Daly, MD • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New cancer drug ABBV-400 enters early human testing
Disease control OngoingThis early-phase trial tests an investigational drug called ABBV-400 in about 300 adults with advanced solid tumors, including liver, pancreatic, breast, and ovarian cancers. The study aims to see if the drug can shrink tumors and to check for side effects. Participants receive A…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Experimental cocktail aims to revive immune attack on Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of an experimental immune booster (N-803) with standard checkpoint inhibitors in people with advanced solid tumors (like lung, bladder, or skin cancer) whose disease progressed after prior immunotherapy. The goal is to see if the combo can shrink tu…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug combo shows promise in early cancer trial
Disease control OngoingThis early-stage study tests two experimental immunotherapy drugs, ABBV-927 and ABBV-181, in people with advanced solid tumors that have not responded to other treatments. The main goal is to find the safest dose and understand how the drugs move through the body. About 163 parti…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New antibody combo aims to supercharge immune system against Hard-to-Treat cancers
Disease control OngoingThis early-phase trial is testing an experimental drug called INBRX-106, alone or combined with the immunotherapy Keytruda, in people with advanced solid tumors (including lung, head and neck, melanoma, and others) that have stopped responding to standard treatments. The main goa…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Inhibrx Biosciences, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Promising cancer combo trial pulled before it even started
Disease control TerminatedThis study was designed to test whether adding an experimental drug called TTI-101 to the immunotherapy pembrolizumab (Keytruda) is safe and effective for people with head and neck cancer that has returned or spread. The trial was withdrawn before enrolling any participants, so n…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New drug duo aims to boost immune attack on head and neck tumors
Disease control OngoingThis early-phase study tests whether giving two immune-boosting drugs (LVGN7409 and a PD-1 inhibitor) before surgery can safely help the body fight HPV-negative head and neck cancer. About 27 adults with resectable tumors will receive the combination, then undergo surgery. The ma…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Two-Drug combo shows promise in keeping head and neck cancer at bay
Disease control OngoingThis phase 2 trial is testing whether adding lenvatinib to pembrolizumab (Keytruda) after standard chemoradiation can help prevent head and neck cancer from coming back. About 50 patients with advanced, PD-L1 positive cancer will receive either the combination or pembrolizumab al…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Universität des Saarlandes • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Experimental immunotherapy cocktail takes on tough tumors
Disease control OngoingThis early-phase trial is testing a combination of two immunotherapy drugs, naptumomab estafenatox and durvalumab, in 120 people with advanced or metastatic solid tumors like pancreatic, ovarian, and lung cancer. The main goal is to find a safe dose and see how the body reacts. R…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: NeoTX Therapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New drug duo hopes to boost immune system against tough cancers
Disease control OngoingThis early-stage trial is testing a new drug called HFB200301, either alone or with another drug (tislelizumab), in 72 adults with advanced solid tumors like lung, stomach, or skin cancer. The main goal is to check safety and find the best dose. Researchers will also watch for an…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: HiFiBiO Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Head and neck cancer trial pulled before it even started
Disease control TerminatedThis study was designed to see if adding low-dose radiotherapy to a combination of targeted therapy (Afatinib) and immunotherapy (Tislelizumab) before surgery could improve outcomes for people with resectable head and neck cancer. The trial was withdrawn before enrolling any part…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Experimental drug ARRY-614 paired with immunotherapy shows promise in early cancer trial
Disease control OngoingThis study tests an experimental drug called ARRY-614 combined with standard immunotherapies (nivolumab or nivolumab plus ipilimumab) in people with advanced solid tumors, including lung, head and neck, kidney, and skin cancers. The first part of the trial finds the safest dose, …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New hope for advanced cancers: ABBV-400 enters human trials
Disease control OngoingThis early-phase study tests an experimental drug called ABBV-400, alone or with another drug (bevacizumab), in about 520 adults with advanced solid tumors including lung, stomach, and colorectal cancers. The goal is to find the safest and most effective dose and see if it can sh…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New antibody IMT-009 tested in patients with advanced cancers
Disease control OngoingThis early-phase trial tests a new antibody drug called IMT-009, given alone or with the cancer pill fruquintinib, in about 67 people with advanced solid tumors or lymphomas that have stopped responding to standard treatments. The main goals are to find a safe dose, understand si…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Immunitas Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New immunotherapy cocktail takes on head and neck cancer
Disease control OngoingThis phase 2 trial is testing whether combining the immunotherapy drug tislelizumab with other experimental drugs (surzebiclimab or alcestobart) can shrink tumors or slow cancer growth in people with advanced head and neck cancer that has come back or spread. About 160 participan…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Immunotherapy may replace chemo in head and neck cancer trial
Disease control OngoingThis study tests whether the immunotherapy drug pembrolizumab (Keytruda) combined with radiation works better than the standard chemotherapy drug cisplatin with radiation for patients with a certain type of head and neck cancer (p16-positive). About 126 adults with advanced or in…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Loren Mell, MD • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Head and neck cancer trial pulled before it began
Disease control TerminatedThis pilot study aimed to test the safety of adding the drug Temsirolimus (Torisel) to standard chemoradiotherapy for people with advanced head and neck cancer. The goal was to find a safe dose of Temsirolimus when given alongside radiation and other chemotherapy drugs like Cetux…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug duo takes on tough head and neck cancers
Disease control OngoingThis phase II trial tests a new drug called SI-B001 combined with the chemotherapy paclitaxel in 42 adults with recurrent or metastatic head and neck squamous cell carcinoma. Participants have already tried standard treatments like immunotherapy or platinum chemo. The study aims …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug SI-B001 tested for tough head and neck cancers
Disease control OngoingThis phase 2 trial tests a drug called SI-B001 in 11 adults with head and neck cancer that has returned or spread after prior treatments like chemotherapy and immunotherapy. The drug is given weekly through an IV. Researchers are checking if it can shrink tumors and how safe it i…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Could adding chemo to precision radiation boost survival in head and neck cancer?
Disease control OngoingThis phase 2 trial compares stereotactic radiotherapy alone versus radiotherapy plus chemotherapy for people with head and neck cancer that has spread to 1-3 other spots in the body. The main goal is to see if the combination helps patients live at least one year without a drop i…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Groupe Oncologie Radiotherapie Tete et Cou • Aim: Disease control
Last updated Jun 26, 2026 13:05 UTC
-
New chemo combo aims to help laryngeal cancer patients keep their voice
Disease control OngoingThis Phase 3 trial tests whether giving a three-drug chemotherapy regimen (docetaxel, cisplatin, and fluorouracil) before radiotherapy helps people with advanced laryngeal or hypopharyngeal cancer avoid losing their voice box. The standard approach is to give cisplatin during rad…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Groupe Oncologie Radiotherapie Tete et Cou • Aim: Disease control
Last updated Jun 26, 2026 12:59 UTC
-
New Light-Based scanner could spot hidden cancer in neck lymph nodes
Diagnosis TerminatedThis study is testing a new imaging device called MSOT that uses light and sound to create detailed pictures of neck lymph nodes in people with head and neck cancer. The goal is to see if it can more accurately detect cancer spread and radiation-induced scarring than current meth…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: University of Oklahoma • Aim: Diagnosis
Last updated Jun 27, 2026 09:00 UTC
-
New radioactive tracer aims to spot hidden cancer in lymph nodes
Diagnosis TerminatedThis pilot study tests a radioactive imaging agent called 111In-panitumumab in 28 people with head and neck cancer. The goal is to see if it can safely and accurately find cancer in lymph nodes compared to the standard dye method used during surgery. The study is currently suspen…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Stanford University • Aim: Diagnosis
Last updated Jun 27, 2026 08:06 UTC
-
New online tool aims to ease life after head and neck cancer
Symptom relief OngoingThis trial tests a web-based tool called HN-STAR that helps head and neck cancer survivors and their doctors manage ongoing health issues after treatment. About 357 survivors from 20 to 36 cancer clinics will either use the tool or get usual care. The goal is to see if the tool i…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Could a cheap gout pill soothe radiation burns?
Symptom relief OngoingThis early-stage study tests whether a low dose of colchicine, a medicine usually used for gout, can safely reduce skin redness and pain caused by radiation therapy in people with head and neck cancer. About 30 participants take one pill daily during their radiation treatment. Th…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Rutgers, The State University of New Jersey • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
AI-Powered symptom watch aims to keep head and neck cancer patients out of the ER
Symptom relief OngoingThis study tests whether using machine learning to closely monitor symptoms can help head and neck cancer patients avoid urgent hospital visits during radiation therapy. Researchers will compare intensive symptom tracking plus standard care to standard care alone in 72 patients w…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Roswell Park Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
Proton beam vs. standard radiation: which is gentler on head and neck cancer patients?
Symptom relief OngoingThis study compares proton beam radiation to standard photon radiation (IMRT) for people with head and neck cancer. The goal is to see if proton therapy causes fewer side effects, like painful mouth sores, by exposing less healthy tissue to radiation. About 108 adults with certai…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
Blood test aims to catch hidden head and neck cancer early
Knowledge-focused OngoingThis study is testing whether a blood test can find tiny bits of tumor DNA (ctDNA) or HPV DNA in patients with high-risk head and neck cancer after standard treatment. The goal is to see if this test can detect cancer that remains or comes back earlier than usual scans. The study…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Can we predict who will benefit from immunotherapy? new study aims to find out.
Knowledge-focused OngoingThis study is looking for biological markers (biomarkers) that might predict how well patients with certain types of squamous cell carcinoma respond to a type of immunotherapy called PD-1 inhibitors. Researchers will analyze blood and tumor tissue samples from 800 patients, both …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
3D tumor maps could sharpen radiation targeting in head and neck cancer
Knowledge-focused OngoingThis study tests whether creating a virtual 3D map of a patient's removed tumor helps doctors plan radiation therapy more precisely. Researchers will compare standard radiation plans with plans that include the 3D map to see if it changes the treatment area or reduces radiation t…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Sponsor: Vanderbilt University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Can a Tumor's 'Neighborhood' predict drug success?
Knowledge-focused OngoingThis study reviews medical records from 300 cancer patients to see if the makeup of a tumor's surroundings (the tumor microenvironment) is linked to how well antibody-based therapies work. Researchers will analyze tissue samples and blood markers from patients with seven types of…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Does more frequent Check-Ups after head and neck cancer save lives?
Knowledge-focused OngoingThis study looks at whether a more intensive follow-up schedule after treatment for head and neck cancer helps people live longer compared to a standard schedule. It involves 197 smokers or heavy drinkers over age 35 who are cancer-free 2-4 months after treatment. The goal is to …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Cancer test study pulled before it even started
Knowledge-focused TerminatedThis study planned to check if a new test, called OncoPrism-HNSCC, could predict how well immunotherapy would work in people with head and neck cancer that had spread. Researchers would have looked at tumor samples taken before treatment to see if the test could tell who would be…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Sponsor: Cofactor Genomics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
New study examines immunotherapy outcomes in american indian cancer patients
Knowledge-focused OngoingThis study reviews medical records of 72 American Indian patients treated with immunotherapy for cancers like lung cancer, melanoma, and kidney cancer. Researchers compare their outcomes—such as how long the cancer is controlled and side effects—to those of White patients. The go…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Sponsor: University of Oklahoma • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
New MRI technique may reveal cancer treatment effects earlier
Knowledge-focused OngoingThis study tests whether a special type of MRI, called diffusion MRI, can accurately measure how head and neck tumors change during chemotherapy and radiation. Researchers will scan 16 patients before and during treatment to see if the MRI can predict whether the cancer shrinks o…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: NYU Langone Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC